Advertisement
AKBA vs ATOS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKBA is a StrongBuy and ATOS is a StrongBuy.
AKBA's RSI Indicator is sitting in oversold zone for 6 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where AKBA advanced for three days, in 227 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
AKBA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AKBA as a result. In 60 of 72 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for AKBA turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 37 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AKBA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for AKBA entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.483) is normal, around the industry mean (11.138). P/E Ratio (-4.878) is within average values for comparable stocks, (-7.600). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (1.115) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. AKBA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AKBA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
ATOS in upward trend: price may jump up because it broke its lower Bollinger Band on September 24, 2026
ATOS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 27 of 33 cases where ATOS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on ATOS as a result. In 71 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for ATOS just turned positive on October 02, 2026. Looking at past instances where ATOS's MACD turned positive, the stock continued to rise in 41 of 51 cases over the following month. The odds of a continued upward trend are 80%.
ATOS moved above its 50-day moving average on October 13, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ATOS crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 65%.
Following a +16.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where ATOS advanced for three days, in 180 of 231 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The 10-day RSI Indicator for ATOS moved out of overbought territory on October 19, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 26 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 52 cases where ATOS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATOS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for ATOS entered a downward trend on October 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 42 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.941) is normal, around the industry mean (2.988). P/E Ratio (-0.583) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. ATOS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATOS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
AKBA | ATOS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 52 | 18 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 46 Fair valued | 53 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 98 | |
PRICE GROWTH RATING 1..100 | 92 | 63 | |
P/E GROWTH RATING 1..100 | 8 | 42 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AKBA's Valuation (46) in the Biotechnology industry is in the same range as ATOS (53) in the Medical Specialties industry. This means that AKBA’s stock grew similarly to ATOS’s over the last 12 months.
AKBA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ATOS (100) in the Medical Specialties industry. This means that AKBA’s stock grew similarly to ATOS’s over the last 12 months.
ATOS's SMR Rating (98) in the Medical Specialties industry is in the same range as AKBA (99) in the Biotechnology industry. This means that ATOS’s stock grew similarly to AKBA’s over the last 12 months.
ATOS's Price Growth Rating (63) in the Medical Specialties industry is in the same range as AKBA (92) in the Biotechnology industry. This means that ATOS’s stock grew similarly to AKBA’s over the last 12 months.
AKBA's P/E Growth Rating (8) in the Biotechnology industry is somewhat better than the same rating for ATOS (42) in the Medical Specialties industry. This means that AKBA’s stock grew somewhat faster than ATOS’s over the last 12 months.
| AKBA | ATOS | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 88% | 2 days ago 87% |
| Stochastic ODDS (%) | 2 days ago 82% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 83% | 2 days ago 79% |
| MACD ODDS (%) | 2 days ago 86% | 2 days ago 80% |
| TrendWeek ODDS (%) | 2 days ago 87% | 2 days ago 87% |
| TrendMonth ODDS (%) | 2 days ago 87% | 2 days ago 78% |
| Advances ODDS (%) | about 1 month ago 84% | 9 days ago 78% |
| Declines ODDS (%) | 2 days ago 86% | 2 days ago 87% |
| BollingerBands ODDS (%) | 2 days ago 76% | 2 days ago 82% |
| Aroon ODDS (%) | 2 days ago 86% | 2 days ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AKBA’s FA Score shows that 1 FA rating(s) are green while ATOS’s FA Score has 0 green FA rating(s).
- AKBA’s FA Score: 1 green, 4 red.
- ATOS’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AKBA’s TA Score shows that 4 TA indicator(s) are bullish while ATOS’s TA Score has 6 bullish TA indicator(s).
- AKBA’s TA Score: 4 bullish, 4 bearish.
- ATOS’s TA Score: 6 bullish, 4 bearish.
Price Growth
AKBA (@Pharmaceuticals: Generic) experienced а -16.62% price change this week, while ATOS (@Biotechnology) price change was -8.99% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.94%. For the same industry, the average monthly price growth was -9.84%, and the average quarterly price growth was +9.53%.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
Reported Earning Dates
AKBA is expected to report earnings on Nov 09, 2026.
ATOS is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-2.94% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
@Biotechnology (-1.10% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
AKBA and
Correlation & Price change
A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with IPSC. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then IPSC could also see price increases.
| Ticker / NAME | Correlation To AKBA | 1D Price Change % | ||
|---|---|---|---|---|
| AKBA | 100% | -5.31% | ||
| IPSC - AKBA | 38% Loosely correlated | -1.83% | ||
| SYRE - AKBA | 37% Loosely correlated | +1.70% | ||
| FENC - AKBA | 36% Loosely correlated | -0.76% | ||
| RXRX - AKBA | 36% Loosely correlated | -0.55% | ||
| KYMR - AKBA | 36% Loosely correlated | -0.73% | ||
More | ||||